Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 2010

View Archived Issues

DDP IV inhibitor ASP-4000 has long-lasting effects in preclinical studies

Liposomal amphotericin B is noninferior to conventional therapy in visceral leishmaniasis

Preclinical studies point to potential of NB-003 in treating acne

AG-2 described as new biomarker for ovarian cancer

Albumin therapy to be evaluated in acute ischemic stroke in ongoing phase III trial

AstraZeneca discloses novel JAK2 inhibitors for cancer therapy

GlaxoSmithKline presents new interferon inducers

Merck & Co. describes novel gamma-secretase modulators

NeuroSearch patents new nicotinic acetylcholine alpha7 receptor modulators

Aastrom treats final patient in phase II trial of cardiac repair cells in dilated cardiomyopathy

Lundbeck reports on fourth quarter 2009, ended December 31

Actelion receives FDA's complete response letter on Zavesca sNDA for Niemann-Pick type C disease

Abbott to acquire Facet Biotech

FDA recommends approval InterMune's Esbriet for idiopathic pulmonary fibrosis

FDA approves Botox for upper limb spasticity in adults

Thymosin beta-4 improves neurological outcome in rat model of stroke

Diamyd Medical advances U.S. phase III trial of Diamyd for diabetes type 1

Limerick BioPharma reports positive phase Ia data on LIM-0705

Cempra completes phase I trials of CEM-101 for community-acquired bacterial pneumonia

Cellzome and GSK enter strategic drug discovery alliance in inflammatory disease

Transgene signs exclusive option agreement with Novartis for NSCLC therapeutic TG-4010

FDA grants orphan drug status to Cytokinetics' CK-2017357 in ALS

Affymax receives milestone payment from Takeda for phase III Hematide trial in Japan

ImmunoCellular's CSC-based vaccine ICT-121 increases survival in animal model of glioblastoma

AMT's gene therapy agent for hemophilia B begins phase I/II trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...